

# SYMATESE

THE SCIENCE OF TISSUE REGENERATION & RECONSTRUCTION,  
AND ITS ADMINISTRATION SYSTEMS FOR THE BENEFIT OF DOCTORS AND PATIENTS.

## Press Release

Bornel, near Paris, France, February 23, 2026

### SYMATESE AND NORDIC PHARMA REINFORCE PARTNERSHIP TO ADVANCE CLINICAL INNOVATION IN DRY EYE DISEASE TREATMENT.

**Bornel, France - February 20, 2026 - SYMATESE Group, a leading expert in the science of Hyaluronic Acid and tissue regeneration, welcomes Nordic Pharma's recent announcement of the European launch of Lacrifill®, a novel dry eye therapy leveraging SYMATESE's proprietary Hyaluronic Acid technological platform, manufactured in France by SYMATESE. Lacrifill® was already successfully launched in the United States and addresses a market of more than 16 million patients.**

Lacrifill®, a product within the Nordic Pharma portfolio is now launched in Europe following CE mark approval and launch in the US in 2025. We are particularly enthusiastic to see this novel dry eye ophthalmic treatment developed as a joint collaboration between SYMATESE and Nordic Pharma made available to more patients worldwide. By combining SYMATESE's expertise in Hyaluronic Acid formulation and manufacturing with Nordic's expertise in clinical development, Lacrifill® delivers a clinically validated, reliably produced treatment for more dry eye patients worldwide.

This milestone will also contribute to accelerating our global rollout in 2026 and beyond. For more information read the [Nordic Pharma Press release](#).

Dry eye disease is a highly prevalent condition, affecting up to 30% of the European population and represents a particular challenge in patients undergoing ocular surgical procedures. Pre-existing ocular surface disease in candidates for cataract or LASIK surgery can compromise surgical outcomes and impact patient satisfaction.

Lacrifill® is a patented cross-linked hyaluronic acid gel designed to temporarily block tear drainage by occluding the canalicular system. By enhancing tear film preservation, Lacrifill® helps keep the eyes bathed in their own natural tears, offering an individualized approach to dry eye management. The in-office procedure provides a full fill of the canalicular system and delivers long-lasting effects for up to six months.

#### About SYMATESE

With 27 years of existence, SYMATESE has established itself as a leading expert in the science of tissue regeneration. Thanks to cutting-edge research and its technological platform integrating collagen, hyaluronic acid, silicones and thermoplastics, the company develops innovative medical solutions that transform patients' lives and revolutionize practices in some fifteen medical specialties. With its continued commitment to research and development, SYMATESE is accelerating its global rollout in 2026 already initiated in 2024 and is well positioned to continue shaping the future of healthcare including regenerative and aesthetic medicine. Visit us at <http://www.symatесе.com> and follow us on [LinkedIn](#).